{
    "body": "Is lenvatinib effective for renal cell carcinoma?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27467136", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27267515", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24190702", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27690664", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27047959", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24387233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26482279", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27339111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27621699"
    ], 
    "ideal_answer": [
        "Yes, combination of lenvatinib and everolimus is approved to treat advanced or metastatic renal cell carcinoma."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002292", 
        "http://www.disease-ontology.org/api/metadata/DOID:4450", 
        "http://www.disease-ontology.org/api/metadata/DOID:4451"
    ], 
    "type": "yesno", 
    "id": "589a245778275d0c4a000024", 
    "snippets": [
        {
            "offsetInBeginSection": 221, 
            "offsetInEndSection": 406, 
            "text": "However, the combination of lenvatinib, a multitargeted agent that inhibits VEGF as well as FGF receptors, and everolimus demonstrated promising results in a randomized phase II trial. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27047959", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 119, 
            "text": "The FDA has approved the combination of lenvatinib and everolimus to treat advanced or metastatic renal cell carcinoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267515", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1386, 
            "offsetInEndSection": 1642, 
            "text": "Moreover, a recent Phase II study demonstrated a significant benefit for the second-line combination treatment with everolimus plus lenvatinib (a novel TKI) in terms of progression-free survival and overall survival compared to the single-agent everolimus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621699", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 769, 
            "offsetInEndSection": 1030, 
            "text": "We then discuss two recently approved growth factor receptor antagonists i.e. cabozantinib and lenvatinib, and a recently approved checkpoint inhibitor, nivolumab, and issues pertaining to drug development, and future directions in treatment of metastatic RCC. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27690664", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2654, 
            "offsetInEndSection": 2878, 
            "text": "INTERPRETATION: Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26482279", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 84, 
            "text": "Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339111", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 85, 
            "text": "Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27339111", 
            "endSection": "title"
        }
    ]
}